**Supplemental Digital Content 3**

**TABLE. MS Practice Characteristics of Respondents (N=239)**

|  |  |
| --- | --- |
| **Characteristic** | **Respondents, n (%)a** |
| **PWMS treated with a DMDb** | |
| <100 | 71 (29.7) |
| 100-300 | 93 (38.9) |
| 301-600 | 51 (21.3) |
| 601-1000 | 14 (5.9) |
| >1000 | 10 (4.2) |
| **Length of time managing PWMS** | |
| >15 years | 44 (25.5) |
| >5 to ≤15 years | 134 (56.1) |
| 0 to ≤5 years | 44 (18.4) |
| **Rolec** | |
| MS treatment decision making | 95 (39.8) |
| Patient education and support | 221 (92.5) |
| Management of GI AEs related to DMF | 162 (67.8) |
| Prescribing MS therapies | 48 (20.1) |

Percentages may not sum to 100% because of rounding.

Abbreviations: AE, adverse event; DMF, delayed-release dimethyl fumarate; DMD, disease-modifying drug; GI, gastrointestinal; MS, multiple sclerosis; PWMS, persons with multiple sclerosis.

aN=239.

bIn the last 12 months.

cSome providers may play multiple roles.